Al's Comment:

 This abstract shows a much smaller overall survival benefit to adding Temodar at the same time as radiation than the "Stupp" report... only a 1.25 month advantage to adding Temodar to radiation.  It also points out that there are more side effects when adding Temodar to radiation. They conclude that we should question if the standard therapy is worth it.

My thoughts: this is a smaller study and not randomized as the Stupp studt was..so I tend to put more importance on the Stupp study - I wouldn't get rid of the standard therapy yet based on this study but it does show the need for more research.


Posted on: 01/06/2013

Acta Neurochir (Wien). 2012 Dec 20. [Epub ahead of print]

Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.

Gutenberg A, Bock HC, Reifenberger G, Brück W, Giese A.

Department of Neurosurgery, University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany, agutenberg@uni-mainz.de.

 

Abstract

BACKGROUND: 

To compare survival and hematological toxicity rates between two postoperative therapy regimens in patients with primary glioblastoma (GBM), namely temozolomide (TMZ) concomitant to radiation, followed by adjuvant TMZ, versus adjuvant TMZ after radiation only.

 

PATIENTS AND METHODS: 

A total of 191 patients with primary GBM were postoperatively treated with either radiation and concomitant TMZ, followed by adjuvant TMZ (Stupp protocol) (n = 154), or radiation followed by adjuvant TMZ (n = 37). The incidence of hematological adverse effects (AE) was recorded for all patients. From both treatment groups, 26 patients were matched according to age, Karnofsky performance scale (KPS) score, and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation.

 

RESULTS: 

Hematological AEs were mild in both unmatched groups, but were significantly more frequent in the concomitant plus adjuvant TMZ group (p < 0.001). Matched-pair analysis confirmed significantly more frequent hematological AEs in the concomitant and adjuvant group compared to the sequential (adjuvant) TMZ group (p = 0,012). Patients treated with concomitant plus adjuvant TMZ showed significantly longer progression-free survival (PFS) (10.6 versus 6.6 months; p = 0.014), but no prolonged overall survival (OS) (16.9 vs. 15.6 months; p = 0.717) compared to patients who received the sequential treatment regimen.

 

CONCLUSION: 

In this retrospective study, the OS in patients with primary GBM treated with sequential TMZ following radiation appeared to be similar to that in patients treated with concomitant plus adjuvant TMZ. Given the significantly higher risk of hematological AE for concomitant treatment, the role of concomitant plus adjuvant TMZ use compared to sequential administration of TMZ, especially for patients with MGMT-unmethylated tumors, should be further evaluated.

 

 PMID: 23254891 [PubMed - as supplied by publisher] 

 

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!